Novartis, CH0012005267

Bank of America keeps CHF 150.00 target for Novartis stock

Published on 10/15/2026 at 11:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rhapsido won FDA approval on October 7, 2026 for symptomatic dermographism. Novartis stock costs EUR 133.45 on October 15, 2026.

Recent company milestones

Novartis received FDA approval for Rhapsido on October 7, 2026.
Second-quarter revenue reached USD 14.95 billion and net income USD 3.26 billion.
Novartis stock trades at EUR 133.45 at 10:49 a.m. CEST at Lang & Schwarz on October 15, 2026.

Futuristisches Forschungsgebäude mit ovaler Glasfassade und Spiegelteich im Vordergrund — Novartis AG CH0012005267 – Futuristisches Forschungsgebäude mit ovaler Glasfassade, Spiegelteich und Grünanlagen, Illustration mit AI erstellt.

Bank of America Securities kept its Buy rating and CHF 150.00 target for Novartis on October 12, 2026, as TipRanks reported. Novartis stock was trading at EUR 133.45 at Lang & Schwarz on October 15, 2026 at 10:49 a.m. CEST.

Three milestones shape the story

Novartis received FDA approval for Rhapsido, also known as remibrutinib, on October 7, 2026, for adults with symptomatic dermographism. The company said twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 compared with placebo, according to its Novartis newsroom.

In chronological order, Novartis reported second-quarter 2026 net sales growth of 3 percent in US dollars on July 21, 2026, while reaffirming full-year guidance. On October 7, Rhapsido received FDA approval, with the pivotal trial showing twice as many complete hive resolutions by Week 12 versus placebo. On October 12, Bank of America Securities maintained its Buy rating and CHF 150.00 price target, according to TipRanks.

What does the pipeline signal mean?

The operating base remains substantial. Novartis generated USD 14.95 billion in revenue, USD 3.26 billion in net income attributable to common shareholders and USD 1.71 in diluted earnings per share in the second quarter of 2026. The figures come from the standardized financial record for the period ended June 30, 2026. The company also reaffirmed low-single-digit full-year sales growth and low-single-digit core operating-income decline for 2026 in its second-quarter communication.

Two dates follow in October

The next scheduled company dates are the Remibrutinib in MS investor call on October 23, 2026, and Novartis third-quarter results on October 27, 2026, both listed on the company's investor calendar. The October 27 report is the next major financial checkpoint for the stock.

Stock trades at Lang and Schwarz

For investors, the near-term question is whether the new Rhapsido indication can add commercial weight before the October results and the November capital markets event referenced by Bank of America Securities. The company combines a fresh regulatory milestone with a second-quarter revenue base of USD 14.95 billion and a CHF 150.00 analyst target.

Novartis stock was trading at EUR 133.45 at Lang & Schwarz on October 15, 2026 at 10:49 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Novartis stock.